Source: Eur Respir J 2011; 37: 218-220
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Dumitrescu D., Seck C., ten Freyhaus Henrik., Gerhardt F., Erdmann E., Rosenkranz S.. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011; 37: 218-220

Member's Comments

No comment yet.

Related content which might interest you: Primary pulmonary hypertension associated with CD8/T-cell large granulocyte leukemia Source: Eur Respir J 2001; 18: Suppl. 33, 521s Year: 2001 Pulmonary hypertension in patients with chronic myeloproliferative disorders Source: Eur Respir J 2010; 35: 1396-1406 Year: 2010 Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia Source: Eur Respir J 2009; 33: 670-672 Year: 2009 Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020 Pulmonary myeloid dendritic cell numbers, phenotype and response to lipopolysaccharide in patients with chronic obstructive pulmonary disease Source: Annual Congress 2010 - Mechanisms of asthma and lung inflammation Year: 2010 Treatment of pulmonary hypertension in chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313 Year: 2006 Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Pulmonary hypertension associated with ponatinib therapy Source: Eur Respir J 2016; 47: 676-679 Year: 2016 Features of the chemiluminescent activity of neutrophils in chronic obstructive pulmonary disease associated with multiple myeloma Source: Virtual Congress 2020 – Clinical characteristics and diagnostic tools for phenotyping asthma and COPD Year: 2020 Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Phenotypic characteristics of patients with arterial hypertension and chronic obstructive pulmonary disease Source: Annual Congress 2012 - COPD comorbidities I Year: 2012 Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 1514-1516 Year: 2016 Bosentan and pulmonary hypertension in patients affected by chronic obstructive pulmonary disease Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Arterial stiffness in patients with chronic obstructive pulmonary disease combined with arterial hypertension Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity Year: 2020 Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Pulmonary hypertension in patients with chronic myeloproliferative disorders Source: Eur Respir Rev 2015; 24: 400-410 Year: 2015 Effects of Valsartan on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease (COPD) and secondary pulmonary hypertension Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Pulmonary veno-occlusive disease in myeloproliferative disorder Source: Eur Respir J 2009; 33: 213-216 Year: 2009 The rate of pulmonary thromboembolism in acute exacerbation of chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 297s Year: 2005